Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

Core Insights - Axsome Therapeutics reported $150.04 million in revenue for Q2 2025, a year-over-year increase of 72.1% [1] - The company’s EPS for the same period was -$0.92, an improvement from -$1.24 a year ago [1] - Revenue exceeded the Zacks Consensus Estimate of $139.61 million by 7.47%, and EPS also surpassed expectations by 8% [1] Revenue Breakdown - Royalty revenue was $1.08 million, below the nine-analyst average estimate of $1.74 million, reflecting a year-over-year increase of 67.7% [4] - Product sales, net totaled $148.96 million, exceeding the nine-analyst average estimate of $135.37 million, with a year-over-year increase of 72.2% [4] - Product sales for Sunosi reached $30 million, surpassing the six-analyst average estimate of $25.75 million [4] - Product sales for Auvelity were $119.6 million, compared to the $110.79 million average estimate from six analysts [4] Stock Performance - Axsome shares have returned -2.3% over the past month, while the Zacks S&P 500 composite increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]